Anthony Doyle, Chief Financial Officer at BIOCRYST PHARMACEUTICALS INC (BCRX), bought 36,300 shares at $5.57 ($202K) on 2024-05-14, disclosed to the SEC on 2024-05-15.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Something here stands out, but not much.
| Filing → |
| BCRX | BUY | 2020-08-12 | $220K | — | Filing → |